Identification

Generic Name
Peptide YY (3-36)
DrugBank Accession Number
DB05004
Background

Peptide YY (3-36), a synthetic human PYY 3-36, is a compound being evaluated for the treatment of obesity. It reduces appetite and increases satiety in obese patients.

Type
Small Molecule
Groups
Investigational
Synonyms
  • Pyy (3-36) peptide
  • PYY 3-36
  • PYY(3-36)
  • PYY3-36
External IDs
  • AC162352
  • GT-001

Pharmacology

Indication

Investigated for use/treatment in metabolic disease and obesity.

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

PYY 3-36 acts via the presynaptic Y2 receptor in the ARC. It decreases neuropeptide Y (NPY) release from static hypothalamic explants and thus acts to decrease food intake.

TargetActionsOrganism
UNeuropeptide Y receptor type 2Not AvailableHumans
UNeuropeptide Y receptor type 1Not AvailableHumans
UNeuropeptide Y receptor type 5Not AvailableHumans
UNeuropeptide Y receptor type 4Not AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
7PQZ90ULIR
CAS number
123583-37-9

References

General References
  1. Chandarana K, Batterham R: Peptide YY. Curr Opin Endocrinol Diabetes Obes. 2008 Feb;15(1):65-72. doi: 10.1097/MED.0b013e3282f3f4b1. [Article]
  2. Sloth B, Davidsen L, Holst JJ, Flint A, Astrup A: Effect of subcutaneous injections of PYY1-36 and PYY3-36 on appetite, ad libitum energy intake, and plasma free fatty acid concentration in obese males. Am J Physiol Endocrinol Metab. 2007 Aug;293(2):E604-9. Epub 2007 Jun 12. [Article]
PubChem Substance
347909887

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedTreatmentObesity (Disorder)1
1CompletedTreatmentFeeding and Eating Disorders1
1CompletedTreatmentHealthy Subjects (HS)1
0CompletedBasic ScienceHealthy Subjects (HS)1
Not AvailableCompletedTreatmentObesity (Disorder)1
Not AvailableNot Yet RecruitingNot AvailableObesity (Disorder)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
Not Available
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Targets

Drugtargets2
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Receptor activity
Specific Function
Receptor for neuropeptide Y and peptide YY. The rank order of affinity of this receptor for pancreatic polypeptides is PYY > NPY > PYY (3-36) > NPY (2-36) > [Ile-31, Gln-34] PP > [Leu-31, Pro-34] N...
Gene Name
NPY2R
Uniprot ID
P49146
Uniprot Name
Neuropeptide Y receptor type 2
Molecular Weight
42730.69 Da
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Peptide yy receptor activity
Specific Function
Receptor for neuropeptide Y and peptide YY. The rank order of affinity of this receptor for pancreatic polypeptides is NPY > [Pro-34] PYY, PYY and [Leu-31, Pro-34] NPY > NPY (2-36) > [Ile-31, Gln-3...
Gene Name
NPY1R
Uniprot ID
P25929
Uniprot Name
Neuropeptide Y receptor type 1
Molecular Weight
44391.535 Da
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Peptide yy receptor activity
Specific Function
Receptor for neuropeptide Y and peptide YY. The activity of this receptor is mediated by G proteins that inhibit adenylate cyclase activity. Seems to be associated with food intake. Could be involv...
Gene Name
NPY5R
Uniprot ID
Q15761
Uniprot Name
Neuropeptide Y receptor type 5
Molecular Weight
50725.99 Da
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Peptide yy receptor activity
Specific Function
Receptor for neuropeptide Y and peptide YY. The rank order of affinity of this receptor for pancreatic polypeptides is PP, PP (2-36) and [Ile-31, Gln-34] PP > [Pro-34] PYY > PYY and [Leu-31, Pro-34...
Gene Name
NPY4R
Uniprot ID
P50391
Uniprot Name
Neuropeptide Y receptor type 4
Molecular Weight
42194.55 Da

Drug created at October 21, 2007 22:23 / Updated at June 12, 2020 16:52